ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,217Medicare Part D Prescriptions Filled, Including Refills

Rank: 5 out of 18

$446K Total Retail Price of All Prescriptions

Rank: 5 out of 18

939 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
26% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 939 patients filled at least one prescription for a schedule two drug, compared to an average of 12%.

Schedule Three
Controlled Substances

16% of this provider’s 939 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

1% of this provider’s 10,433 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

14% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$40 was the average price of a prescription from this provider, compared to $44 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
LISINOPRIL 814 776 1 1
LOVASTATIN 667 642 2 13
OMEPRAZOLE 595 557 3 6
HYDROCODONE-ACETAMINOPHEN 549 500 S3 4 3
SIMVASTATIN 466 419 5 5
LEVOTHYROXINE SODIUM 422 412 6 2
METFORMIN HCL 408 379 7 11
METOPROLOL TARTRATE 399 383 8 8
ALENDRONATE SODIUM 359 352 9 20
HYDROCHLOROTHIAZIDE 319 300 10 22
AMLODIPINE BESYLATE 305 297 11 7
FUROSEMIDE 199 185 12 4
WARFARIN SODIUM 176 175 13 9
LISINOPRIL-HYDROCHLOROTHIAZIDE 161 144 14 58
PAROXETINE HCL 157 141 15 52
GABAPENTIN 148 143 16 10
SPIRIVA 146 135 17 37
METOPROLOL SUCCINATE 146 125 17 38
CITALOPRAM HBR 127 121 19 16
PRAVASTATIN SODIUM 124 122 20 75
ALLOPURINOL 123 120 21 53
POTASSIUM CHLORIDE 117 99 22 12
ZOLPIDEM TARTRATE 116 113 23 17
ATENOLOL 109 107 24 21
DOXAZOSIN MESYLATE 107 106 25 115
ADVAIR DISKUS 105 90 26 42
GLYBURIDE 101 95 R 27 57
NAPROXEN 90 89 28 90
CLOPIDOGREL 88 86 29 41
DONEPEZIL HCL 86 86 30 14
AZITHROMYCIN 84 78 31 104
GLIPIZIDE 83 74 32 36
BENAZEPRIL HCL 82 77 33 97
ATORVASTATIN CALCIUM 82 71 33 47
LOSARTAN POTASSIUM 74 70 35 31
ALCOHOL SWABS 74 64 35 128
INSULIN SYRINGE 70 65 37 91
CARVEDILOL 69 59 38 26
FINASTERIDE 58 58 39 67
PLAVIX 57 57 40 48
TRIAMTERENE-HCTZ 53 53 41 63
ISOSORBIDE MONONITRATE ER 52 52 42 87
TAMSULOSIN HCL 51 47 43 29
HYDRALAZINE HCL 50 44 44 54
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 1, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.